ClinicalTrials.gg
RecruitingNCT03638505Qual-PSPUpdated Jan 8, 2024

Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy

An observational study in Progressive Supranuclear Palsy, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-08.

Sponsored by Assistance Publique Hopitaux De Marseille · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Supranuclear Palsy, Progressive with a site in France — 6 open to participants now, 6 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · France.

Started
2019
the only one that year
Observational
6 of 22
3 open now
Registered
14th of 22
by date
Lead sponsor
3 of 22
Assistance Publique Hopitaux De Marseille

Among the 22 studies in Supranuclear Palsy, Progressive with a site in France, this one is the only one that started in 2019, is one of 6 observational ones, and was the 14th registered.

Supranuclear Palsy, Progressive

171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.

Browse Supranuclear Palsy, Progressive studies →

Open to participants now

6 of the 22 studies in Supranuclear Palsy, Progressive with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Supranuclear Palsy, Progressive with a site in France, or all of them as a file.
02

Study summary

Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease from the parkinsonian syndrome group.

PSP is characterised by the association of a non-doparesponsive parkinsonian syndrome with axial signs. The latter predominantly manifest as a psycho-motor slowness, an apathy and frontal executive deficits. Swallowing impairments may additionally provoke life-threatening situations. Today the treatment is mostly symptomatic as no cure is available. Given the limited treatment options and its clinical characteristics, PSP deeply impact on the patients' quality of life (QoL) as well as on their caregivers'. Nevertheless a limited number of studies have focused on these aspects. A better understaning of the factors determining both patient and cargiver QoL may help optimising their care.

the principal objective of this study is to identify the determinants of PSP patients' QoL.

The secondary objectives are : i) to identify the determinants (medical, behavioural, socio-economic, environmental ...) of PSP patients' caregivers' QoL and burden ; ii) to validate in French language the QoL scale specific for PSP available in English (PSP-QoL).

This is a multidisciplinary transversal study. 2 subject groups will be included : i) PSP patients ; ii) caregiver of PSP patients (designated by the patient as being the person closest to them), Data collected : i) from the patient : socio-demographic, social and professionnal environment, clinical (disease duration and severity, neuropsychological evaluation), therapeutic, mood, anxiety, coping, body image, QoL ; ii) from the caregiver: socio-demographic, social and professionnal environment, connection with the patient, data relative to their own health, mood, anxiety, coping, QoL, burden.

Progress : patient information, designation of a caregiver, consent collection, collection of data Statistical analysis : To address the principal objective 'patient' QoL scores will be confronted to the other collected variables (Student's t-test, correlation coefficient). The results will be adjusted to the confounding factors using multivariate analyses.

Read the detailed description

Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease from the parkinsonian syndrome group. It represents 5 to 10% of all parkinsonian syndromes and affects 3000 to 10000 persons in France.

PSP is characterised by the association of a non-doparesponsive parkinsonian syndrome with axial signs such as early gait instability and falls, oculomotor signs such as a vertical gaze limitation and both cognitive and behavioural disturbances. The latter predominantly manifest as a psycho-motor slowness, an apathy and frontal executive deficits. Swallowing impairments may additionally provoke life-threatening situations. Today the treatment is mostly symptomatic as no cure is available. Given the limited treatment options and its clinical characteristics, PSP deeply impact on the patients' quality of life (QoL) as well as on their caregivers'. Nevertheless a limited number of studies have focused on these aspects. A better understaning of the factors determining both patient and cargiver QoL may help optimising their care.

Objectives : the principal objective of this study is to identify the determinants (motor, behavioural, socio-economic, environemental...) of PSP patients' QoL.

The secondary objectives are : i) to identify the determinants (medical, behavioural, socio-economic, environmental ...) of PSP patients' caregivers' QoL and burden ; ii) to validate in French language the QoL scale specific for PSP available in English (PSP-QoL).

Methods : This is a multidisciplinary transversal study. Population : 2 subject groups will be included : i) PSP patients ; ii) caregiver of PSP patients (designated by the patient as being the person closest to them), Data collected : i) from the patient : socio-demographic, social and professionnal environment, clinical (disease duration and severity, neuropsychological evaluation), therapeutic, mood, anxiety, coping, body image, QoL ; ii) from the caregiver: socio-demographic, social and professionnal environment, connection with the patient, data relative to their own health, mood, anxiety, coping, QoL, burden.

Progress : patient information, designation of a caregiver, consent collection, collection of data Statistical analysis : To address the principal objective 'patient' QoL scores will be confronted to the other collected variables (Student's t-test, correlation coefficient). The results will be adjusted to the confounding factors using multivariate analyses. To address the secondary objective, 'caregiver' QoL and burden scores will be confronted to the other collected variables through the same procedure. The transcultural validation of the PSP-QoL scale will be obtained using standard methodology: forward-backward method, acceptability test, study of metric properties.

Expected results and impact: This work will help understanding the social handicap in PSP and may lead to new therapeutic strategies.

Relevance of the project: No data on PSP-related QoL or caregiver burden are available in France In addition, the factors determining these aspects of the disease are poorly understood. The motor handicap obviously reduces patients' QoL and increases the caregivers' burden. However the impact of the cognitive and behavioural disturbances and particularly the reduction of social interactions on the QoL of patients and caregiver burden have been less studied.

03

Conditions studied

  • Progressive Supranuclear Palsy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

PSP patients with their caregivers

Eligibility criteria

Inclusion Criteria (patients)

Female or male, age ≥ 40 years at the time of onset of symptoms

  • diagnosis of possible or probable PSP according to the criteria of Litvan (1996b)
  • agreeing to participate in the study
  • subject with no severe cognitive impairment (MMS> 20/30)
  • subject who does not have psycho-behavioral comorbidity deemed to be severe enough to make his assessment impossible
  • subject not presenting a measure of legal protection

Exclusion Criteria (patients)

  • Age \<40 years at the onset of symptoms
  • Diagnosis other than PSP (including other Parkinsonian syndromes)
  • Presence of another concomitant neurological disease
  • subject with severe cognitive impairment (MMS≤20 / 30)
  • subject presenting psycho-behavioral comorbidities considered sufficiently severe to make it impossible to evaluate
  • subject under legal protection
  • subject not affiliated to a social security scheme

Inclusion Criteria (caregivers)

  • Female or male, age ≥ 18 years
  • designated by the patient as the person closest to him / her
  • agreeing to participate in the study
  • subject affiliated to a social security scheme

Exclusion Criteria (caregivers)

  • Age \<18 years
  • Not designated by the patient as the person closest to him / her
  • Not agreeing to participate in the study
  • subject not affiliated to a social security scheme
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • patients

    patients with Progressive supranuclear palsy. PSP-QoL will be performed in this group

    Other: PSP-QoL

  • caregiver

    the caregiver of the patient with Progressive supranuclear palsy PSP-QoL will be performed in this group

    Other: PSP-QoL

Interventions

  • OtherPSP-QoL

    PSP-QoL is a patient-reported outcome measure for progressive supranuclear palsy (PSP). The Supranuclear Palsy Quality of Life scale (PSP-QoL) may be a helpful patient-reported scale for clinical trials and studies in PSP. PSP-QoL consists of 28 items scored on a 3- or 5-point Likert scale, with the total score ranging from 0 to 100. Each item is scored from either 0 to 4, with the exception of four items, which are scored from 0 to 2, with higher scores indicating more-severe disability or movement abnormality. Items are in six categories: daily activities (by history); behavior; bulbar; ocular motor; limb motor; and gait/midline. The scale includes comments and/or instructions for each item and word anchors to explain the ratings.

06

What researchers measure

Primary outcomes

  1. score of PSP-QoL questionnaire

    the score obtained by group will be compare Progressive Supranuclear Palsy (PSP) Quality of Life questionnaire by Schrag and collaborators in 2006. 14 items, 5 degree from no problem, slight problem, moderate problem, marked problem to extreme problem (1 to 5 points) minimum score:14 maximum score : 70

    Time frame: 1 hour

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Jul 2026, 84 months after the start.

Of 37 observational studies under Supranuclear Palsy, Progressive, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 54. This study's planned 84 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2018
First posted
Aug 20, 2018
StartActual
Jul 4, 2019
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Jan 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03638505
Responsible party
Sponsor
First posted
Aug 20, 2018
Start date
Jul 4, 2019
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jan 8, 2024

Study contacts

ALEXANDRE EUSEBIO, MD
Contact
Alexandre.EUSEBIO@ap-hm.fr
+33 491384360
EMILIE GARRIDO PRADALIE
study director · APHM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion